EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Longitudinal Follow‐Up of the Specific Antibody Response to SARS‐CoV‐2 Vaccination in Colombia

Myriam Arévalo-Herrera, Bladimiro Rincón-Orozco, John Mario González-Escobar, Sonia Marcela Herrera-Arévalo iD, Elena Carrasquilla-Agudelo, Paula Andrea Serna-Ortega, Sebastián Quiceno-García, Nicolas Palacio-Muñoz, Brandon Rosero-López, Ernesto Mondol-Miranda, Ivette Freyle-Roman, Brayan Mendoza-Landinez und 10 weitere

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70133 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Myriam Arévalo-Herrera und 21 weiteren Autor:innen. Beteiligte Einrichtung: Centro Internacional de Vacunas, Cali, Colombia. Hauptthemen laut MEDLINE: Antibodies, Viral, COVID-19, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This research was supported by the Colombian Ministry of Science and Technology (Ministerio de Ciencia y Tecnología de Colombia). Programa Nacional de Ciencia,….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A total of 5011 adult volunteers attending vaccination centers in different regions of Colombia were enrolled in a 1‐year prospective observational cohort study to evaluate the immunogenicity and effectiveness of SARS‐CoV‐2‐based vaccines as part of a National Vaccine Program established to contain the COVID‐19 pandemic. Following informed consent, 5,011 participants underwent a sociodemographic survey and PCR testing to assess SARS‐CoV‐2 infection. Blood samples were collected, and serum fractions were obtained from a participant subsample ( n = 3441) at six‐time points to assess virus‐specific IgG responses to the Spike protein, its Receptor Binding Domain, and the Nucleoprotein by ELISA. Additionally, antibody‐neutralizing activity was evaluated using a cPass SARS‐CoV‐2 neutralization kit. Most participants (95.8%; n = 4802) received between one Ad26. COV2.S (Janssen vaccine) and four vaccine doses of BNT162b2 (Pfizer/BioNTech), AZD1222 (AstraZeneca), mRNA‐1273 (Moderna), CoronaVac (Sinovac), with some receiving vaccine combinations; a small group, 4.2% ( n = 209), remained unvaccinated. Throughout the study, only 8.76% ( n = 439) of the participants tested positive for SARS‐CoV‐2 by PCR. Notably, all participants seroconverted for IgG antibodies, with high seropositivity rates for S (99.8%; n = 4795), RBD (99.7%; n = 1691), and N (92.7%; n = 3072) proteins. Moreover, significant (92%–97%) neutralizing activity was observed for all four SARS‐CoV‐2 circulating variants. This study highlights the importance of assessing the duration of the IgG response to SARS‐CoV‐2 elicited by vaccination and infection, and the antibody neutralizing activity as a potential surrogate marker of protection. These findings provide important insight for further strengthening the vaccination strategies to control COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralCOVID-19COVID-19 VaccinesSARS-CoV-2HumansColombiaAdultMaleFemaleMiddle AgedImmunoglobulin GAntibodies, NeutralizingProspective StudiesSpike Glycoprotein, CoronavirusYoung AdultLongitudinal StudiesAgedAdolescentFollow-Up StudiesVaccinationBNT162 VaccineAntibody Formation

Stichwörter der Autor:innen

COVID‐19SARS‐CoV‐2antibodyneutralizationvaccines

Substanzen

Antibodies, ViralCOVID-19 VaccinesImmunoglobulin GAntibodies, NeutralizingSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2BNT162 Vaccine

Autor:innen und Institutionen

  • Centro Internacional de Vacunas, Cali, Colombia.
  • Universidad Industrial de Santander, Escuela de Medicina, Bucaramanga, Colombia.
  • Universidad de los Andes, Bogotá, Colombia.
  • Fundación Santa Fe de Bogotá, Salud Poblacional, Colombia.
  • Departamento de Medicina Interna, Sección de Infectología, Fundación Santa Fe de Bogotá.

ORCID-Profile: Sonia Marcela Herrera-Arévalo

Förderung

  • This research was supported by the Colombian Ministry of Science and Technology (Ministerio de Ciencia y Tecnología de Colombia). Programa Nacional de Ciencia,…

Zitieren

APA

Arévalo-Herrera, M., Rincón-Orozco, B., González-Escobar, J. M., Herrera-Arévalo, S. M., Carrasquilla-Agudelo, E., Serna-Ortega, P. A., Quiceno-García, S., Palacio-Muñoz, N., Rosero-López, B., Mondol-Miranda, E., Freyle-Roman, I., Mendoza-Landinez, B., Mora-Guevara, E., Santos-Barbosa, J. C., Bohórquez-Martínez, F., Bolaños-Cristancho, N., Jiménez-Serna, M., Nieto-Rojas, M. A., Suarez-Zamora, D., …, & Herrera-Valencia, S. (2025). Longitudinal Follow‐Up of the Specific Antibody Response to SARS‐CoV‐2 Vaccination in Colombia. Journal of Medical Virology. https://doi.org/10.1002/jmv.70133

Vancouver

Arévalo-Herrera M, Rincón-Orozco B, González-Escobar JM, Herrera-Arévalo SM, Carrasquilla-Agudelo E, Serna-Ortega PA, et al. Longitudinal Follow‐Up of the Specific Antibody Response to SARS‐CoV‐2 Vaccination in Colombia. Journal of Medical Virology. 2025. doi:10.1002/jmv.70133

BibTeX
@article{ArvaloHerrera2025,
  author = {Arévalo-Herrera, Myriam and Rincón-Orozco, Bladimiro and González-Escobar, John Mario and Herrera-Arévalo, Sonia Marcela and Carrasquilla-Agudelo, Elena and Serna-Ortega, Paula Andrea and Quiceno-García, Sebastián and Palacio-Muñoz, Nicolas and Rosero-López, Brandon and Mondol-Miranda, Ernesto and Freyle-Roman, Ivette and Mendoza-Landinez, Brayan and Mora-Guevara, Eliana and Santos-Barbosa, Juan Carlos and Bohórquez-Martínez, Francisco and Bolaños-Cristancho, Natalia and Jiménez-Serna, Mónica and Nieto-Rojas, María A and Suarez-Zamora, David and Quintero-Espinosa, Juliana and Londoño-Trujillo, Darío and Herrera-Valencia, Sócrates},
  title = {Longitudinal Follow‐Up of the Specific Antibody Response to SARS‐CoV‐2 Vaccination in Colombia},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70133}
}
Kostenlos starten →